Prostate Cancer - Results from #120

Causes of evolutionary divergence in prostate cancer. April 2, 2025

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. April 1, 2025

Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. April 1, 2025

Emulating an Existing Trial of Treatments for Prostate Cancer Using Real-World Data: Challenges and lessons learned. April 1, 2025

Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. April 1, 2025

The Use of PI-FAB Score in Evaluating mpMRI After Focal Ablation of Prostate Cancer: Is It Reliable? Inter-Reader Agreement in a Tertiary Care Referral University Hospital. April 1, 2025

Patterns of Care and Treatment Outcomes Among Men Diagnosed with Prostate Cancer from Culturally and Linguistically Diverse Backgrounds: A Scoping Review. April 1, 2025

Curium Completes the Acquisition of Monrol as Part of Its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint March 31, 2025

The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review. March 31, 2025

Transperineal Focal Laser Ablation of the Prostate for Prostate Cancer: A Systematic Review of the Literature. March 31, 2025

Developments in Ultrasound-Based Imaging for Prostate Cancer Detection. March 31, 2025

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer. March 31, 2025

A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer. March 31, 2025

A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. March 31, 2025

Evaluation of Candidates for Upfront Docetaxel Therapy Among Patients With Metastatic Castration-sensitive Prostate Cancer from a Retrospective Multicenter Study (MAHOROBA study). March 31, 2025

The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. March 29, 2025

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. March 29, 2025

Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. March 29, 2025

Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy. March 29, 2025

FDA Approves Novartis Radioligand Therapy Pluvicto® for Earlier Use Before Chemotherapy in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer March 28, 2025

Page 7 of 1474